VP-16-213 is clearly active in small cell bronchogenic carcinoma. Further, there appears to be no cross resistance between this drug and other commonly used agents in this disease. The response rate of 25% seen in this study, in a patient population with advanced disease, is comparable to the response rates for other active single agents including cyclophosphamide, adriamycin, vincristine, methotrexate, procarbazine, and the nitrosoureas. Furthermore, the very predictable and generally mild toxicity of this drug makes it a potentially ideal agent to use in combination regimens in small cell bronchogenic carcinoma.
|Original language||English (US)|
|Number of pages||2|
|Journal||Cancer Treatment Reports|
|State||Published - Dec 1 1977|
ASJC Scopus subject areas
- Cancer Research